News | 11 August 2021
Lupin posts net profit of Rs 542.46 cr. in Q1FY22
The profits were bolstered by the Boehringer Ingelheim MEK program income
The profits were bolstered by the Boehringer Ingelheim MEK program income
Formulation business grew by 15 per cent in the quarter
KIMS Hospitals' brand, has an aggregate bed capacity of 3,064, including over 2,500 operational beds as of March 31, 2021
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Nearly 6,000 patients have been treated with the drug since 2017
The drug is indicated for mild and transient episodes of heart block
The company posted net profit of Rs.34.24 crores for the period ended June 30, 2020.
PAT rises to Rs 195.76 crore
India business contributes to a stellar performance
Forex gains stood at Rs 20 crore for the quarter
Ibuprofen and Famotidine Tablets is an AB-rated generic therapeutic equivalent version of Horizon Medicines LLC’s Duexis Tablets, 800 mg/26.6 mg
This robust growth has come despite the raging pandemic for most part of the quarter
The proposed acquisition will further bolster Strides US presence through acquisition of a multi dosage facility in the US.
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
The company has been consistently reducing debt
It had an estimated market size of US $ 32 million as of June 2021
EPS climbs to Rs 9.25 for the quarter
It is part of the company’s pain/analgesics portfolio of OTC products
Subscribe To Our Newsletter & Stay Updated
